Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma

Next Previous
Trial Profile

GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obinutuzumab (Primary) ; Pixantrone (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms GOAL

Most Recent Events

  • 01 Aug 2022 Primary endpoint has not been met (Objective overall response rate after six treatment cycles or the individual end of treatment) , according to Results published in the British Journal of Haematology
  • 01 Aug 2022 Final results published in the British Journal of Haematology
  • 30 Mar 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top